We are searching data for your request:
Upon completion, a link will appear to access the found materials.
Research group finds new way to reverse heart failure
Heart failure, which experts call heart failure, is one of the most common diseases in western countries. In Germany alone, the number of people affected is estimated at two to three million. If left untreated, the disease can be fatal. Researchers are now reporting on a new therapeutic approach to reverse heart failure.
Just a few days ago, the Hannover Medical School (MHH) reported in a message that a research team discovered therapeutically effective natural substances in the search for new therapies for heart failure. Now Hanoverian researchers have provided further insights into the therapy of heart failure.
Switch off the block in the human genome
As the MHH explains in a current press release, the heart is no longer able to pump a sufficient amount of blood through the body in the event of heart failure or heart failure. This can result in organs, muscles or other tissues no longer being adequately supplied with oxygen and nutrients.
So far, the disease has been treated with drugs that lower blood pressure and relieve the heart. Professor Dr. Dr. Thomas Thum from the Hannover Medical School (MHH) is taking a new approach.
According to the information, the head of the Institute for Molecular and Translational Therapy Strategies (IMTTS) and his team have found a way to switch off the building block in the human genome that regulates the pathological enlargement of the heart muscle at the beginning of heart failure.
The research results were published in the renowned journal "Nature Communications".
Special substance developed
When searching for so-called non-coding RNAs that control certain processes in the cells, the research team came across the microRNA-132 (MiR-132). "It acts like a regulatory main switch and is found much more frequently in the heart muscle cells in animals and people with various heart diseases than in healthy people," explains Professor Thum.
In order to switch off MiR-132, the scientists at IMTTS have developed a special substance. The AntimiR-132 compound is constructed as a so-called antisense oligonucleotide like a mirror image of MiR-132 and intercepts the pathologically increased occurrence of the microRNA.
"In our studies in the large animal model, we were able to show that the use of AntimiR-132 can lower the miR-132 level in the heart muscle cells and reverse severe heart failure," says Professor Thum.
Stop swallowing tablets
According to the announcement, the AntimiR-132 has been developed under the name CDR at Cardior Pharmaceuticals, a biopharmaceutical company that specializes in the development of innovative cardiac therapeutics based on the research work of cardiologist Professor Thum.
"We have already tested our key substance CDR on the basis of the data in our publication in patients with heart failure," explains the cardiologist. Those affected are examined whether a few administrations of the compound already show therapeutic effects without side effects being observed.
According to the information, further clinical studies will follow to further test the effectiveness and safety of the preparation.
Professor Thum hopes that next-generation therapy could receive marketing approval in five years. The constant tablet taking would then be a thing of the past. "One infusion per month will probably be enough for effective treatment," estimates the expert. (ad)
Author and source information
This text corresponds to the specifications of the medical literature, medical guidelines and current studies and has been checked by medical doctors.
- Hannover Medical School (MHH): New therapeutic approach to reverse heart failure, (accessed: 03.02.2020), Hannover Medical School (MHH)
- Ariana Foinquinos, Sandor Batkai, Celina Genschel, Janika Viereck, Steffen Rump, Mariann Gyöngyösi, Denise Traxler, Martin Riesenhuber, Andreas Spannbauer, Dominika Lukovic, Natalie Weber, Katrin Zlabinger, Ena Hašimbegović, Johannes Winkler, Jan Fiedler, Seema Dangwal, Martin Fischer , Jeanne de la Roche, Daniel Wojciechowski, Theresia Kraft, Rita Garamvölgyi, Sonja Neitzel, Shambhabi Chatterjee, Xiaoke Yin, Christian Bär, Manuel Mayr, Ke Xiao & Thomas Thum: Preclinical development of a miR-132 inhibitor for heart failure treatment; in: Nature Communications, (published: January 31, 2020), Nature Communications
- Hannover Medical School (MHH): Natural substances against fibrosis and diastolic heart failure discovered, (accessed: 03.02.2020), Hannover Medical School (MHH)